Historical Stock Chart
2 Months : From Sep 2019 to Nov 2019
By Colin Kellaher
Merck & Co. (MRK) on Wednesday said China's National Medical Products Administration approved the company's cancer drug Keytruda as monotherapy for the first-line treatment in certain patients with non-small cell lung cancer.
The Kenilworth, N.J., drug maker said the approval covers patients with locally advanced or metastatic non-small cell lung cancer whose tumors express PD-L1 as determined by a NMPA-approved test, with no EGFR or ALK genomic tumor aberrations.
Merck said Keytruda is the first anti-PD-1 therapy approved in China as both monotherapy and in combination with chemotherapy for the first-line treatment of appropriate patients with non-small cell lung cancer, the most common type of lung cancer.
Write to Colin Kellaher at email@example.com
(END) Dow Jones Newswires
October 02, 2019 08:24 ET (12:24 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.